Premixed insulin aspart 30: Control and convenience in type 1 and type 2 diabetes

被引：0
|
作者：
Boehm, B
Home, PD
Bott, U
Behrend, C
Kamp, NM
Lindholm, A
机构：
来源：
DIABETES | 2000年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
395
引用
收藏
页码：A98 / A98
页数：1
相关论文
共 50 条
  • [31] Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes
    Valentine, William J.
    Pollock, Richard F.
    Plun-Favreau, Juliette
    White, Jeremy
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1399 - 1412
  • [32] Biphasic insulin aspart in the treatment of type 2 diabetes mellitus
    Cucinotta, Domenico
    Russo, Giuseppina T.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (17) : 2905 - 2911
  • [33] Efficacy of biphasic insulin aspart in patients with type 2 diabetes
    Halimi, S
    Raskin, P
    Liebl, A
    Kawamori, R
    Fulcher, G
    Yan, G
    [J]. CLINICAL THERAPEUTICS, 2005, 27 : S57 - S74
  • [34] COST-MINIMIZATION ANALYSIS OF INSULIN LISPRO 50/50 VERSUS INSULIN ASPART 30/70 PREMIXED FORMULATIONS IN TYPE II DIABETES
    Yousefi, N.
    Taheri, S.
    Sheikhi, S.
    Amani, B.
    Akbarzadeh, A.
    Peiravian, F.
    [J]. VALUE IN HEALTH, 2019, 22 : S573 - S574
  • [35] External continuous subcutaneous infusion of insulin using insulin aspart (NovoLog®) in subjects with type 1 and type 2 diabetes
    Schorr, Alan
    Wittlin, Steven
    Weng, Wayne
    Howard, Campbell
    [J]. DIABETES, 2006, 55 : A457 - A457
  • [36] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [37] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
  • [38] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
    Mishriky, Basem M.
    Tanenberg, Robert J.
    Cummings, Doyle M.
    [J]. DIABETES, 2017, 66 : A252 - A252
  • [39] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
  • [40] Premixed insulin regimens in type 2 diabetes: pros
    Maiorino, Maria Ida
    Bellastella, Giuseppe
    Esposito, Katherine
    Giugliano, Dario
    [J]. ENDOCRINE, 2017, 55 (01) : 54 - 59
12345